sets), we identified a large subset of pipeline data that was available to Nelson et al., but that was excluded from analysis because Pharmaprojects reported an inactive status, most commonly “No Development Reported”. Instead of directly using Pharmaprojects development status, we use other fields in the database to label drugs with a latest historical development phase (see Methods, S2 Text), enabling us to use 83% of this data in our analysis.
